Biomarkers as a guide for antimicrobial therapy

Area of Science:

• Biomarker research
• Infectious disease diagnostics
• Antimicrobial stewardship

Background:

• Antibiotic misuse and resistance are significant global health challenges.
• Biomarkers are crucial for guiding appropriate antibiotic therapy and infection management.
• Procalcitonin is the most studied biomarker for infection and sepsis detection.

Purpose of the Study:

• To evaluate the efficacy and safety of procalcitonin as a biomarker for guiding antibiotic use.
• To assess the impact of procalcitonin-guided therapy on patient outcomes and antibiotic consumption.
• To explore novel diagnostic tools for differentiating infection from non-infectious inflammation.

Main Methods:

• Systematic review and analysis of 11 randomized controlled trials involving over 3500 patients.
• Evaluation of procalcitonin testing in various clinical settings including ICU, emergency, and primary care.
• Comparison of procalcitonin-guided antibiotic therapy with standard management protocols.

Main Results:

• Procalcitonin use led to a 35-70% reduction in antibiotic prescriptions without apparent negative impact on patient outcomes in most studies.
• Studies primarily focused on lower respiratory tract infections, with limited data on surgical infections, immunocompromised patients, and sepsis.
• Concerns remain regarding potential excess mortality (7.5-10% difference allowed in non-inferiority trials) with procalcitonin-guided therapy.

Conclusions:

• Procalcitonin is a valuable tool for reducing antibiotic overuse, particularly in lower respiratory tract infections.
• Further research is needed to confirm safety and efficacy in diverse patient populations and complex infections.
• Advanced diagnostics like transcriptomic and proteomic marker panels show promise but require clinical validation.